Faron Pharmaceuticals Oy (DI) (FARN)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

185.00p
   
  • Change Today:
      10.00p
  • 52 Week High: 262.50p
  • 52 Week Low: 141.67p
  • Currency: UK Pounds
  • Shares Issued: 112.92m
  • Volume: 145,938
  • Market Cap: £208.91m

Latest ShareCast News

Faron strengthens bexmarilimab potential with fresh trial data

By Josh White

Date: Monday 20 Oct 2025

(Sharecast News) - Faron Pharmaceuticals said on Monday that updated results from its phase one and two 'BEXMAB' study showed further improvement in the clinical performance of bexmarilimab, strengthening the drug's profile as a treatment for newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS).

Faron narrows first-half losses as it advances its lead asset

By Josh White

Date: Wednesday 27 Aug 2025

(Sharecast News) - Faron Pharmaceuticals reported a series of first-half clinical and financial milestones on Wednesday, as it advanced its lead asset, bexmarilimab, through late-stage development in high-risk myelodysplastic syndromes (HR-MDS).

Faron secures FDA pathway for lead cancer therapy

By Josh White

Date: Monday 18 Aug 2025

(Sharecast News) - Faron Pharmaceuticals said on Monday that it has secured a clear regulatory pathway for the potential approval of its lead cancer therapy bexmarilimab, following positive feedback from the US Food and Drug Administration.

Faron Pharmaceuticals appoints chief business of... 21-May-2025 ShareCast
Faron enters financing arrangement with Heights ... 03-Apr-2025 ShareCast
Faron identifies final patient in BEXMAB phase t... 31-Jan-2025 ShareCast
Faron Pharmaceuticals reports regulatory progres... 02-Dec-2024 ShareCast
Faron announces promising MDS trial results 27-Nov-2024 ShareCast
Faron Pharmaceuticals files new patent for Cleve... 11-Nov-2024 ShareCast
Faron Pharmaceuticals candidate gets FDA fast tr... 27-Aug-2024 ShareCast
Faron gets positive FDA feedback on bexmarilimab... 11-Jul-2024 ShareCast
Faron Pharmaceuticals extends funding agreement ... 30-Apr-2024 ShareCast
Faron Pharmaceuticals CFO stands down 15-Apr-2024 ShareCast
Faron Pharmaceuticals taps Juho Jalkanen for CEO 08-Apr-2024 ShareCast
Faron shares jump on encouraging trial data 18-Mar-2024 ShareCast
Faron Pharmaceuticals reports year of clinical p... 13-Mar-2024 ShareCast
Faron Pharmaceuticals shores up cash with EUR 3.... 04-Mar-2024 ShareCast
Faron launches second phase of leukaemia treatme... 09-Jan-2024 ShareCast
Faron unveils promising antibody study results 11-Dec-2023 ShareCast
Faron publishes cancer immunotherapy study findi... 07-Dec-2023 ShareCast
 

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

FARN Market Data

Currency UK Pounds
Share Price 185.00p
Change Today 10.00p
% Change 5.71 %
52 Week High 262.50p
52 Week Low 141.67p
Volume 145,938
Shares Issued 112.92m
Market Cap £208.91m

FARN Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
Market averageMarket averageMarket averageMarket averageMarket average
41.46% below the sector average41.46% below the sector average41.46% below the sector average41.46% below the sector average41.46% below the sector average
Price Trend
Market averageMarket averageMarket averageMarket averageMarket average
54.55% above the sector average54.55% above the sector average54.55% above the sector average54.55% above the sector average54.55% above the sector average
Income Not Available
Growth Not Available

What The Brokers Say

Strong Buy 1
Buy 3
Neutral 0
Sell 1
Strong Sell 1
Total 6
neutral
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

FARN Dividends

No dividends found

Trades for 24-Oct-2025

Time Volume / Share Price
16:35 25,000 @ 185.00p
16:35 8,000 @ 185.00p
16:35 7,000 @ 185.00p
16:35 10,000 @ 185.00p
16:29 5,472 @ 186.20p

FARN Key Personnel

CEO Juho Jalkanen
Chair Tuomo Pätsi

Top of Page